Overview

The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Status:
Completed
Trial end date:
2013-09-25
Target enrollment:
Participant gender:
Summary
Protocol is intended to characterize the overall safety and tolerability of eculizumab in this population.
Phase:
Phase 2
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Eculizumab